More recently, Tavolimab (alias: MEDI0562), a humanised agonistic OX40 IgG1 antibody, was deemed safe in advanced-stage solid tumours but PR was observed in only 2 out of 50 patients, not comprising the single HCC patient included (130). This evidence concerns the gene TNFRSF4 and hepatocellular carcinoma.